Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Operating Leases (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Operating Leases data on record, last reported at $110.2 million in Q1 2026.

  • On a quarterly basis, Operating Leases rose 35.93% to $110.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $110.2 million, a 35.93% increase, with the full-year FY2025 number at $111.5 million, up 70.9% from a year prior.
  • Operating Leases reached $110.2 million in Q1 2026 per PCVX's latest filing, down from $111.5 million in the prior quarter.
  • Over the last five years, Operating Leases for PCVX hit a ceiling of $111.5 million in Q4 2025 and a floor of $7.8 million in Q3 2023.
  • A 5-year average of $41.4 million and a median of $20.2 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 6371.11% in 2022, then tumbled 41.74% in 2023.
  • Tracing PCVX's Operating Leases over 5 years: stood at $12.9 million in 2022, then surged by 71.4% to $22.1 million in 2023, then soared by 194.96% to $65.2 million in 2024, then soared by 70.9% to $111.5 million in 2025, then dropped by 1.12% to $110.2 million in 2026.
  • Business Quant data shows Operating Leases for PCVX at $110.2 million in Q1 2026, $111.5 million in Q4 2025, and $78.7 million in Q3 2025.